Note: This document contains side effect information about ibandronate. Some of the dosage forms listed on this page may not apply to the brand name Boniva.
Common side effects of Boniva include: bronchitis and arthralgia. Other side effects include: myalgia. See below for a comprehensive list of adverse effects.
Applies to ibandronate: oral tablet
Other dosage forms:
Along with its needed effects, ibandronate (the active ingredient contained in Boniva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking ibandronate:
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking ibandronate:
Symptoms of overdose
Some side effects of ibandronate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to ibandronate: intravenous kit, intravenous solution, oral tablet
The most serious reported adverse reactions are anaphylactic reaction/shock, atypical fractures of the femur, osteonecrosis of the jaw, and ocular inflammation.
The most frequently reported adverse reactions are arthralgia and influenza-like symptoms, typically associated with the first dose, generally of short duration, mild, or moderate intensity.
Very common (10% or more): Dyspepsia (up to 12%)
Common (1% to 10%): Diarrhea, tooth disorder, vomiting, gastritis, constipation, gastroenteritis abdominal pain, esophagitis, nausea, sore throat
Uncommon (0.1% to 1%): Hemorrhage, duodenal ulcer, dysphagia, dry mouth
Very common (10% or more): Upper respiratory infection (up to 34%)
Common (1% to 10%): Bronchitis, pneumonia, pharyngitis, influenza, nasopharyngitis, asthma exacerbation
Uncommon (0.1% to 1%): Chest pain
Very common (10% or more): Hypocalcemia
Postmarketing reports: Hypocalcemia
Decreased renal calcium excretion may be accompanied by a fall in serum phosphate levels not requiring therapeutic measures. The serum calcium level may fall to hypocalcemic values.
Very common (10% or more): Back pain (14%)
Common (1% to 10%): Pain in the extremity, myalgia, joint disorder, arthritis, arthralgia, localized osteoarthritis, muscle cramp
Postmarketing reports: Severe or incapacitating bone, join, or muscle pain (musculoskeletal pain); osteonecrosis of the jaw; atypical, low-energy, or low-trauma fractures of the femoral shaft; atypical subtrochanteric and diaphyseal femoral fractures
Common (1% to 10%): Hypertension
Uncommon (0.1% to 1%): Phlebitis, thrombophlebitis
Common (1% to 10%): Urinary tract infection, cystitis
Common (1% to 10%): Increased gamma-glutamyl transpeptidase (GGT) levels
Common (1% to 10%): Allergic reaction
Rare (less than 0.1%): Facial swelling/edema, urticaria
Postmarketing reports: Anaphylactic reaction/shock with fatalities, angioedema, bronchospasm, asthma exacerbations, rash, Stevens-Johnson syndrome, erythema multiforme, and dermatitis bullous
Common (1% to 10%): Redness or swelling at the injection site
Common (1% to 10%): Headache, dizziness, paraesthesia, dysgeusia (taste perversion)
Common (1% to 10%): Asthenia, vertigo, influenza-like illness, peripheral edema
Uncommon (0.1% to 1%): Malaise, pain
Combination of influenza-like illness and acute phase reaction has occurred. Influenza-like illness includes events reported as acute phase reaction or symptoms, including myalgia, arthralgia, fever, chills, fatigue, nausea, loss of appetite, and bone pain.
Common (1% to 10%): Insomnia, depression
Common (1% to 10%): Increased creatinine
Uncommon (0.1% to 1%): Azotemia (uremia)
Postmarketing reports: Acute renal failure
Rash occurred in combination of rash pruritic, rash macular, rash papular, rash generalized, rash erythematous, dermatitis, dermatitis allergic, dermatitis medicamentosa, erythema and exanthema.
Uncommon (0.1% to 1%): Pruritus, rash
Uncommon (0.1% to 1%): Anemia, increased blood parathyroid hormone
Postmarketing reports: Ocular inflammation, iritis, uveitis, episcleritis (in some cases, these events resolve only after this drug was discontinued)
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Boniva